Lysosomal glycogen storage disease with normal acid maltase activity

Lysosomal Glycogen Storage Disease with Normal Acid Maltase Activity (LGSD-NAMA), also known as Danon Disease, is a rare genetic disorder characterized by the abnormal accumulation of glycogen in the lysosomes of cells, despite normal activity levels of the enzyme acid maltase. This condition is part of a group of disorders known as glycogen storage diseases (GSDs), which are metabolic disorders affecting the way glycogen is stored and used in the body. Unlike other GSDs, LGSD-NAMA involves a defect in the lysosomal membrane's transporter protein, leading to glycogen accumulation.

Causes

LGSD-NAMA is caused by mutations in the LAMP2 gene, which encodes the lysosome-associated membrane protein 2. This protein is crucial for the normal functioning of lysosomes, including the breakdown and recycling of cellular components. Mutations in the LAMP2 gene disrupt the normal process, leading to the accumulation of glycogen within the lysosomes.

Symptoms

The symptoms of LGSD-NAMA can vary widely among affected individuals but typically include cardiomyopathy (heart muscle disease), muscle weakness, and intellectual disability. The severity and onset of symptoms can also vary, with some individuals experiencing symptoms in childhood, while others may not show symptoms until adolescence or adulthood.

Diagnosis

Diagnosis of LGSD-NAMA involves a combination of clinical evaluation, family history, and genetic testing to identify mutations in the LAMP2 gene. Additional tests, such as enzyme assays to measure acid maltase activity and muscle biopsy to detect glycogen accumulation in lysosomes, may also be used to support the diagnosis.

Treatment

There is currently no cure for LGSD-NAMA, and treatment focuses on managing symptoms and preventing complications. This may include medications to treat heart problems, physical therapy to improve muscle strength, and nutritional support to address metabolic needs. In severe cases, heart transplantation may be considered for individuals with advanced cardiomyopathy.

Prognosis

The prognosis for individuals with LGSD-NAMA varies depending on the severity of symptoms and the onset of the disease. Early diagnosis and management of symptoms can improve the quality of life and potentially extend lifespan, although the disease can be life-threatening, particularly due to complications related to cardiomyopathy.

See Also

• Glycogen storage disease
• Lysosomal storage disease
• Cardiomyopathy
• Genetic disorder

This metabolic disorder related article is a stub. You can help WikiMD by expanding it.